-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $97

Benzinga·11/05/2026 16:00:16
Listen to the news
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $89 to $97.